It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk, which generates more than half of its sales in the United States. Novo, which competes with U.S ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

I’m cautious about Novo Nordisk's stock in the short term due to the recent selloff momentum, which could bottom out if the FDA rejects its petition to restrict compounding alternatives.

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE:NVO) following recent industry developments and competitive insights. The firm said in a note ...

Lisbon-based Novo Banco has been preparing for a possible IPO Private equity firm Lone Star owns majority stake in the bank Police in Portugal are investigating the origin of large amounts of cash ...

The Biden administration said on Tuesday that it would block imports from more than three dozen Chinese companies, citing their alleged ties to forced labor in the Xinjiang region of China.

Given the Republican Party’s track record on worker and union issues, and President-elect Donald Trump’s anti-union first term, it is reasonable to reject the narrative that his party’s ...